Huge shoutout to Chris Lima's lab Memorial Sloan Kettering Cancer Center HHMI for capturing basically the entire ubiquitylation cascade via cryo-EM!!! Congratulations to this creative tour-de-force that follows ubiquitin's path towards a substrate. nature.com/articles/s4158…

Check out our PoC study on a trivalent degrader that leverages dual ligase recruitment to enhance target degradation. Led Adam B. in Alessio Ciulli 's lab, Miquel M. and Cecilia B (Promega). Many future implications, also regarding resistance acquisition. tinyurl.com/2mz4btvz

Congrats Ben!

Great to host ⁦Motonari Uesugi⁩ at ⁦College of Chemistry⁩ today! Great to hear his talk on chemical biology of self assembly!

Development of Ligands and Degraders Targeting MAGE-A3 | Journal of the American Chemical Society pubs.acs.org/doi/10.1021/ja…

Excited about starting the new semester and teaching our Therapeutics Discovery and Development course for UC Berkeley MCB with Roberto Zoncu and Fyodor Urnov !!

New UC Berkeley chancellor Rich Lyons has entrepreneurial ideas to raise potentially $1 billion for campus needs over next 10 years. He also talks about enforcing protest rules, institutional neutrality and more in recent convo. bit.ly/3Z9B6TE

Excited to present our newest paper in J. Am. Chem. Soc. by Qian Shao on using a novel covalent molecular glue of 14-3-3 and ER/YAP/TAZ as a 14-3-3 recruiter for targeted protein localization of nuclear neo-substrates into the cytosol as a new induced proximity approach.

Packed house for the first class of the year for Therapeutic Discovery and Development! ⁦UC Berkeley MCB⁩ #MolecularTherapeutics ⁦Roberto Zoncu⁩ ⁦Fyodor Urnov⁩

Looking forward to giving a talk at this conference in Cambridge, UK in October on covalent drug discovery! my.bps.ac.uk/events/details…

Final version of paralogue-specific EP300 degrader story now out at JACS Au. Congrats to Xuemin Chen, McKenna Crawford, Ying Xiong and our many amazing collaborators ChemBioHub - Huber Lab pubs.acs.org/doi/10.1021/ja…

Curious about how protein damage forms the ever-so-elusive C-terminal cyclic imide? Check out our lab’s newest preprint released earlier this month on bioRxiv 🫡 Congrats to all the authors who contributed to this work 🙌🏼

Congratulations Rick Silverman!

Laurie H. Glimcher, MD, Dana-Farber’s transformative President and CEO, announced today that she will step down on October 1, 2024, and will assume the title of President Emerita. Benjamin Levine Ebert, MD, PhD, chair of Department of Medical Oncology and a world-renowned

The Raymond Moellering lab have created STR22, a synthetic molecule that blocks hard-to-drug proteins like HIFs and XBP1 to curb tumor growth in triple-negative breast cancer, offering a fresh strategy for hypoxia-driven cancers. Raymond Moellering Nature Chemical Biology nature.com/articles/s4158…

The Dickinson Lab is advancing precision medicine with covalent macrocyclic peptides, paving the way for new targeted therapies. Read the full story by visiting our website. bryan dickinson J. Am. Chem. Soc. Tong Lan UChicago News UChicago Biological Sciences UChiPhysicalSciences chemistry.uchicago.edu/news/improving…

The Cravatt Lab, with Bruno Melillo and Evert Njomen, identified novel proteins that could be targeted to delay or even prevent #cancer cell division. Published in Nature Chemistry, this study paves the way for developing innovative cancer therapies. More: ow.ly/jaWL50TeCWB

Imidazoles are Tunable Nucleofuges for Developing Tyrosine-Reactive Electrophiles (K.-L. Hsu et al.) onlinelibrary.wiley.com/doi/10.1002/cb…

Exciting news in drug discovery! Our new preprint introduces BarlowDTI, a cutting-edge method using the Barlow Twins architecture to predict drug-target interactions with state-of-the-art performance. Check it out: arxiv.org/abs/2408.00040 #DrugDiscovery #AI #MachineLearning

Exciting first talk of the ‘24-‘25 #MTx seminar series by Michael Fischbach Michael Fischbach, enthusiastically introduced by Rapé Lab !